Experimental Pancreatic Cancer Drug Nearly Doubles Survival in Phase 3 Trials
Daraxonrasib reduced the risk of death by 60% in a study of patients with metastatic pancreatic cancer, nearly doubling life expectancy compared with controls.
Daraxonrasib: Why the "King of Cancers" Retreated but Did Not Surrender — The Real Limits of the Breakthrough
You saw the headlines. On June 1, 2026, at the annual meeting of the American Society of Clinical Oncology (ASCO), data from the RASolute 302 trial were presented. Revolution Medicines’ daraxonrasib (RMC-6236) cut the risk of death by 60% in patients with metastatic pancreatic adenocarcinoma, nearly doubling median overall survival from 6.6 to 13.2 months.
The media erupted with excitement. "Breakthrough in pancreatic cancer treatment," "End of the chemotherapy era," "Transformative progress" — those were the headlines flooding every feed. Revolution Medicines shares jumped 40% after the results were released.
Yet as an analyst who has tracked targeted therapies for a decade and understands resistance mechanisms from the inside, I see a far more complex picture. Daraxonrasib is unquestionably the biggest step forward in treating the "cancer that kills" in decades. But it is not victory. It is a breather. And the price of that breather is billions of dollars, serious side effects, and, most importantly, the inevitable return of the disease through pathways science has not yet learned to block.
[The Core]: What Is Really Happening
Pancreatic cancer is called the "most RAS-dependent" cancer — mutations in the RAS gene family are found in more than 90% of patients. These mutations drive uncontrolled cell division, allow cells to ignore stop signals, and promote metastasis. More than 85% of cases involve KRAS G12 mutations — G12D (40%), G12V, and G12R.
The first generation of KRAS inhibitors — sotorasib from Amgen and adagrasib from Mirati — work only against the G12C mutation, which appears in just 1–3% of pancreatic cancers. That is like having a key that opens only one door out of a hundred. Daraxonrasib uses a fundamentally different mechanism. It inhibits RAS proteins in their active "ON" state (RAS(ON)), binding them regardless of mutation type.
The RASolute 302 numbers are impressive. Median overall survival reached 13.2 months with daraxonrasib versus 6.7 months with chemotherapy. Objective response rate was 31.6% versus 11.2%. Median progression-free survival was 7.2 months versus 3.6 months. Most importantly, the benefit was consistent across all patients regardless of which RAS mutation their tumor carried.
The key insight that changes everything: Drug efficacy does not equal cure. A median survival of 13.2 months is nearly twice as long as 6.7 months, yet it is still just over a year. In the vast majority of patients the cancer returns. The question is not whether it will return, but when and how.
Studies on resistance mechanisms to RAS inhibitors published between 2025 and 2026 paint a sobering picture. In laboratory models, resistance to drugs like daraxonrasib develops within 7–10 days of treatment start. Cells find ways around the blocked pathway — activating alternative signaling cascades (EGFR, FYN kinases), upregulating other oncogenes, or switching to different metabolic programs.
Timeline and Context
The story of daraxonrasib is the story of a new treatment paradigm moving from lab concept to potential standard of care at record speed, driven by enormous unmet need.
2019–2022: Revolution Medicines develops the concept of "pan-RAS inhibitors" — molecules that block all RAS protein variants rather than one specific form. The key breakthrough is a platform that targets the active "ON-state" RAS, previously considered "undruggable."
2023: Phase 1/2 study RMC-6236-001 begins. Early data show antitumor activity in pancreatic, lung, and colorectal cancers.
June 2024: Bristol Myers Squibb completes its acquisition of Mirati Therapeutics, strengthening its position in KRAS inhibitors. The market realizes the race in this segment has only just begun.
October 2025: FDA grants daraxonrasib "breakthrough therapy" and orphan drug designations for patients with metastatic pancreatic cancer harboring KRAS G12 mutations. The company receives a priority review voucher from the FDA — a mechanism that shortens review time to two months.
February 2026: RASolute 302 data cutoff.
April 2026: Revolution Medicines announces plans to submit a new drug application using the priority voucher.
Early May 2026: FDA authorizes an expanded access program for daraxonrasib in patients with progressive pancreatic cancer, granting approval within 48 hours — unprecedented speed.
June 1, 2026: Full RASolute 302 data presented at ASCO 2026. Expected FDA approval within two to three months of submission.
What matters in this timeline? Speed. From first Phase 1 data to Phase 3 presentation took roughly three years. For oncology, where average drug development takes 8–12 years, this is phenomenal. Yet the pace reflects not only efficacy but also political pressure — pancreatic cancer is the fourth leading cause of cancer death in the USA, and the FDA is willing to make unprecedented concessions.
Winners and Losers
The headlines shout victory for Revolution Medicines. But the real distribution of benefits is far more complex, and the biggest loser is anyone who reads the news and thinks "pancreatic cancer is now curable."
The biggest winner — Revolution Medicines. This is obvious. The company’s shares rose 40% after the announcement. GlobalData analysts project daraxonrasib sales of $1 billion by 2029 and $4.3 billion by 2032. The company has already struck a roughly $2 billion deal with Royalty Pharma in exchange for a share of future revenue. Revolution Medicines has another asset in the same class — RMC-7977 — being studied in combinations. But daraxonrasib is their flagship and it is already delivering.
Second winner — Bristol Myers Squibb. Why? Because in 2024 they acquired Mirati Therapeutics, which owns adagrasib (KRAZATI), a KRAS G12C inhibitor. While the drug works in only 1–3% of mutations, BMS now has infrastructure and experience in RAS-targeted therapy. They are already preparing combinations of adagrasib with other agents to broaden its reach. If daraxonrasib opens the pan-RAS inhibitor market, BMS can quickly bring its own candidates forward.
Third winner — patients and physicians, but with a huge caveat. They finally have an effective tool for second-line therapy. First-line data (RASolute 303) look even more promising: response rates reach 47% with monotherapy and 58% in combination with chemotherapy. This changes treatment standards. But the benefit is temporary — the cancer will return, and physicians will again face the question of what to do next.
The biggest loser — those who think the problem is solved. The most dangerous scenario: a pancreatic cancer patient reads the news, decides a "miracle pill" now exists, and refuses aggressive chemotherapy or surgery while waiting for daraxonrasib. The drug does not work for everyone (ORR 32% means 68% of tumors do not shrink). Even in those it helps, the effect lasts only a limited time. Daraxonrasib is not a replacement for early-stage surgery or for FOLFIRINOX chemotherapy in advanced disease. It is an additional tool, not a cure-all.
Also losing — Amgen and other makers of "older" KRAS inhibitors. Lumakras (sotorasib) from Amgen, approved for G12C-mutant lung cancer, never found wide use in pancreatic cancer because that mutation is rare. The arrival of daraxonrasib, which covers up to 90% of mutations, renders these drugs even more niche.
What the Media Are Not Saying
Yandex.News reports "doubling of survival." But three facts change the picture entirely.
Insight #1: Resistance develops in months, not years.
Recent studies show cancer cells find workarounds almost immediately. In preclinical models, resistance to pan-RAS inhibitors emerged within 7–14 days. Cells either activate alternative signaling pathways (EGFR, FYN kinases), switch to other oncogenic drivers, or alter their metabolic programs.
In the RASolute 302 clinical data, median progression-free survival was 7.2 months. That means half the patients saw their tumors begin growing again within seven months. Seven months is better than 3.6 months on chemotherapy. But it is not "long-term control." It is a delay. The question of what to do when the cancer returns and becomes resistant to daraxonrasib remains unanswered. That is a huge zone of uncertainty.
Insight #2: The toxicity profile requires careful monitoring.
Daraxonrasib has side effects, and they are not trivial. Grade 3 and higher adverse events occurred in 44% of patients on daraxonrasib versus 58% on chemotherapy. That is better than chemotherapy, yet 44% still means nearly every other patient. The most common side effects: rash (14%), stomatitis (12%), diarrhea, and nausea.
Importantly, treatment discontinuation due to side effects was low — 1.2% versus 11.2% on chemotherapy. Toxicity is generally manageable, but it requires active monitoring and supportive care. Patients expecting an "easy pill" may be disappointed. Rash and mouth ulcers are not merely "unpleasant." They can affect quality of life, eating, drinking, and psychological well-being.
Insight #3: The price no one mentions.
Revolution Medicines has not yet announced daraxonrasib’s price. We can extrapolate. Modern targeted oncology drugs cost $10,000–$30,000 per month. KRAZATI (adagrasib) from BMS runs about $20,000 monthly. Lumakras (sotorasib) from Amgen is around $18,000.
If daraxonrasib launches at $15,000–$20,000 per month, annual therapy will cost $180,000–$240,000. Given projected sales of $4.3 billion by 2032 and roughly 60,000 new pancreatic cancer cases in the USA each year (about 50% receiving second-line therapy), the price will land in that range.
Access is the issue. Medicare and private insurers will cover the drug, but with high copays — up to $3,000–$5,000 monthly for patients with high-deductible plans. In countries without universal healthcare or robust insurance systems, the drug will be unavailable. Geographic inequality in pancreatic cancer treatment will widen.
Outlook: The Next 30 and 90 Days
Here is what will realistically happen once the ASCO excitement fades.
Next 30 days: NDA filing and expanded access launch.
Revolution Medicines will announce the exact New Drug Application submission date using its priority voucher. Review is expected to take 6–8 weeks, opening the door to possible approval as early as August–September 2026. The expanded access program approved in May will begin enrolling patients who cannot wait.
At the same time, the first publications on resistance cases from early-phase patients will appear. This will not be a scandal — it is an expected process. Media may frame it as "the drug stops working." The reality is that resistance is inevitable. The question is how quickly scientists can find ways to overcome it.
Analysts will begin revising forecasts. Current consensus sales for 2032 stand at $4.3 billion. If first-line data (RASolute 303) prove as strong as early signals (ORR 58% in combination), the forecast could rise to $6–7 billion. If resistance emerges in most patients within the first six months, it could drop to $2–3 billion.
Next 90 days: Approval decision and commercial launch.
The FDA will likely approve daraxonrasib in September–October 2026. This will be a historic moment — the first pan-RAS inhibitor on the market.
Approval will not be unconditional. The FDA will almost certainly require post-marketing studies (Phase 4) to monitor long-term safety and real-world effectiveness. Given the mechanism (genetic target, prolonged therapy), the agency may also request studies on secondary malignancies — theoretically, altering RAS signaling could affect other cell types.
Competitors will not stand still. Amgen, BMS, Boehringer Ingelheim, and Jacobio Pharmaceuticals (China) will accelerate their own pan-RAS programs. Some may already be in Phase 1–2. If any competitor shows comparable or better efficacy with a more convenient dosing schedule or lower toxicity, Revolution Medicines’ market share could come under pressure within 3–5 years.
What about 12 months from now? Daraxonrasib will become the standard second-line therapy for metastatic pancreatic cancer in the USA, Europe, and possibly Japan. In China the picture is more complex due to regulatory barriers, and local companies (BeiGene, Jacobio) may bring their own analogs to market faster.
The first real-world survival data will emerge — they may be lower than in the clinical trial (RASolute 302 enrolled only patients with good performance status).
Revolution Medicines will begin combination studies of daraxonrasib with immunotherapy (PD-1 inhibitors such as Keytruda). Pancreatic cancer is traditionally "cold" — it does not respond to immunotherapy. There is hope, however, that RAS inhibition may alter the tumor microenvironment and make it vulnerable to the immune system.
Long-term forecast (3–5 years): Pancreatic cancer will remain a "killer cancer," but with an improved prognosis. Median overall survival in metastatic disease will rise from the current 6–12 months to 18–24 months for patients receiving sequential targeted therapy. This is major progress. But it is not a cure.
The central challenge of the next decade is not developing new inhibitors but overcoming resistance. Combinations that attack the tumor from multiple angles simultaneously are needed so the cancer cannot "switch" to a backup pathway. Biomarkers that predict which mutation will emerge first in a given patient are also required.
And honest patient communication is essential. Daraxonrasib is not victory. It is an important battle in a long war. We won this battle. But the war continues.
Daraxonrasib will change treatment standards. It will give patients more time with family, more opportunity to try subsequent lines of therapy, and more chance to live until the next breakthrough. That is an enormous achievement in itself. But calling it "victory over pancreatic cancer" creates false hope. And false hope is the worst enemy of the cancer patient.
— Editorial Team
No comments yet.